Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Condition: Chronic Graft Versus Host Disease Interventions: Drug: Belumosudil; Drug: Rituximab Sponsors: Northside Hospital, Inc.; Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Condition: Large B-cell Lymphoma Interventions: Drug: Prednisone; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Epcoritamab Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
REscue of Nephrons With ALe.F02 (RENAL-F02)
Condition: Glomerulonephritis Rapidly Progressive Interventions: Biological: ALE.F02; Drug: Rituximab; Drug: GlucoCorticoid; Drug: Cyclophosphamid; Drug: Placebo; Drug: Immunosuppressive Agents Sponsor: Alentis Therapeutics AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Condition: Large B-Cell Lymphoma Interventions: Drug: Glofitamab; Drug: Polatuzumab vedotin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Condition: Chronic Graft Versus Host Disease Interventions: Drug: Belumosudil; Drug: Rituximab Sponsors: Northside Hospital, Inc.; Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Condition: Large B-cell Lymphoma Interventions: Drug: Prednisone; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Epcoritamab Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
REscue of Nephrons With ALe.F02 (RENAL-F02)
Condition: Glomerulonephritis Rapidly Progressive Interventions: Biological: ALE.F02; Drug: Rituximab; Drug: GlucoCorticoid; Drug: Cyclophosphamid; Drug: Placebo; Drug: Immunosuppressive Agents Sponsor: Alentis Therapeutics AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Condition: Large B-Cell Lymphoma Interventions: Drug: Glofitamab; Drug: Polatuzumab vedotin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Condition: Chronic Graft Versus Host Disease Interventions: Drug: Belumosudil; Drug: Rituximab Sponsors: Northside Hospital, Inc.; Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Condition: Large B-cell Lymphoma Interventions: Drug: Prednisone; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Epcoritamab Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
REscue of Nephrons With ALe.F02 (RENAL-F02)
Condition: Glomerulonephritis Rapidly Progressive Interventions: Biological: ALE.F02; Drug: Rituximab; Drug: GlucoCorticoid; Drug: Cyclophosphamid; Drug: Placebo; Drug: Immunosuppressive Agents Sponsor: Alentis Therapeutics AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Condition: Large B-Cell Lymphoma Interventions: Drug: Glofitamab; Drug: Polatuzumab vedotin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone Sponsor: Hoffmann-La Roche Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
Condition: Chronic Graft Versus Host Disease Interventions: Drug: Belumosudil; Drug: Rituximab Sponsors: Northside Hospital, Inc.; Sanofi Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Condition: Large B-cell Lymphoma Interventions: Drug: Prednisone; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Vincristine; Drug: Epcoritamab Sponsor: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
REscue of Nephrons With ALe.F02 (RENAL-F02)
Condition: Glomerulonephritis Rapidly Progressive Interventions: Biological: ALE.F02; Drug: Rituximab; Drug: GlucoCorticoid; Drug: Cyclophosphamid; Drug: Placebo; Drug: Immunosuppressive Agents Sponsor: Alentis Therapeutics AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
